Pignata, S., Cecere, S.C. and Di Maio, M. 2016. Bevacizumab as first-line treatment of ovarian cancer: strengths and weaknesses of subgroup analyses:  . Cancer Breaking News. 4, 1 (Mar. 2016), 45–47. DOI:https://doi.org/10.19156/cbn.2016.0009.